Menu
GWAS Study

Refining antipsychotic treatment strategies in schizophrenia: discovery of genetic biomarkers for enhanced drug response prediction.

Chen L, Huai C, Song C et al.

39562719 PubMed ID
GWAS Study Type
2114 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

CL
Chen L
HC
Huai C
SC
Song C
WS
Wu S
XY
Xu Y
YZ
Yi Z
TJ
Tang J
FL
Fan L
WX
Wu X
GZ
Ge Z
LC
Liu C
JD
Jiang D
WS
Weng S
WG
Wang G
ZX
Zhang X
ZX
Zhao X
SL
Shen L
ZN
Zhang N
WH
Wu H
WY
Wang Y
GZ
Guo Z
ZS
Zhang S
JB
Jiang B
ZW
Zhou W
MJ
Ma J
LM
Li M
CY
Chu Y
ZC
Zhou C
LQ
Lv Q
XQ
Xu Q
ZW
Zhu W
ZY
Zhang Y
LW
Lian W
LS
Liu S
LX
Li X
GS
Gao S
LA
Liu A
HL
He L
YZ
Yang Z
DB
Dai B
YJ
Ye J
LR
Lin R
LY
Lu Y
YQ
Yan Q
HY
Hu Y
XQ
Xing Q
HH
Huang H
QS
Qin S
Chapter II

Abstract

Summary of the research findings

Schizophrenia (SCZ) is a severe mental disorder affecting around 1% of individuals worldwide. The variability in response to antipsychotic drugs (APDs) among SCZ patients presents a significant challenge for clinicians in determining the most effective medication. In this study, we investigated the biological markers and established a predictive model for APD response based on a large-scale genome-wide association study using 3269 Chinese schizophrenia patients. Each participant underwent an 8-week treatment regimen with one of five mono-APDs: olanzapine, risperidone, aripiprazole, quetiapine, or amisulpride. By dividing the response into ordinal groups of "high", "medium", and "low", we mitigated the bias of unclear treatment outcome and identified three novel significantly associated genetic loci in or near CDH12, WDR11, and ELAVL2. Additionally, we developed predictive models of response to each specific APDs, with accuracies ranging from 79.5% to 98.0%. In sum, we established an effective method to predict schizophrenia patients' response to APDs across three categories, integrating novel biomarkers to guide personalized medicine strategies.

1,629 Chinese ancestry high-response cases, 485 Chinese ancestry low-response cases

Chapter III

Study Statistics

Key metrics and study information

2114
Total Participants
GWAS
Study Type
No
Replicated
East Asian
Ancestry
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.